Feed ADAP
AD

Adaptimmune Therapeutics plc

ADAP · NASDAQ

$0.05 +8.07% (+$0.00)
Piotroski F-Score Weak
0/9
Valuation
-
N/A
P/E N/A
PEG N/A
EV/EBITDA N/A
Growth
-
N/A
EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
-
N/A
ROIC N/A
Asset turnover N/A
ROE N/A
Debt
-
N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio N/A
Stability
0 /100
Unstable
Beta 2.49x
Rev. volatility N/A
Profitable years N/A

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ADAP
Online

O podjetju

Adaptimmune Therapeutics plc (ADAP) is a biotechnology company focused on the development and commercialization of immunotherapeutic drugs for cancer treatment. The company specializes in developing T-cell receptors (TCRs) and genetically modified T-cells (CAR-T) for therapeutic use in various types of tumors. Adaptimmune aims to create personalized therapeutic approaches that harness the patient's own immune system to fight cancer. With a successful portfolio of clinical studies and a focus on innovation in cancer therapy, shares of Adaptimmune Therapeutics plc (ADAP) may be suitable for investors seeking opportunities in the biotechnology sector with an emphasis on innovative cancer treatments.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Adrian G. Rawcliffe

Employees

506

Headquarters

Abingdon

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.